A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies.
Phase of Trial: Phase I/II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Cancer vaccine MUC-1 (Primary) ; Cancer vaccine MUC-1 (Primary) ; Molgramostim
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Vaxil BioTherapeutics
- 10 Jun 2017 Biomarkers information updated
- 04 Sep 2012 The first two patients have been enrolled into the extension study (VAXIL-002) according to a Vaxil BioTherapeutics media release.
- 29 Aug 2012 Planned end date changed from 1 Oct 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History